STOCK TITAN
  1. Home
  2. News
  3. FMS

Fresenius Medical Care AG - FMS STOCK NEWS

Welcome to our dedicated page for Fresenius Medical Care news (Ticker: FMS), a resource for investors and traders seeking the latest updates and insights on Fresenius Medical Care stock.

Fresenius Medical Care AG & Co. KGaA, a multinational healthcare company headquartered in Germany, is the global leader in kidney dialysis services and products. The company operates over 4,100 dialysis clinics worldwide, treating approximately 345,000 patients as of December 2022. Fresenius Medical Care not only provides comprehensive dialysis treatments but also supplies the essential dialysis products, including machines, dialyzers, and concentrates. With a commanding 35% share of the global dialysis products market, Fresenius is uniquely positioned as the world's only fully integrated dialysis business, providing both services and products.

Services, which encompass care coordination and ancillary operations, contribute around 80% of the company's revenue, while the remaining 20% comes from high-margin products. This business model ensures a strong bottom line, leveraging both operational scale and product innovation.

Fresenius Medical Care is continually enhancing its portfolio and strategic positioning through its Portfolio Optimization Program. Recent news highlights significant progress, including strategic divestitures and market exits to focus on sustainable, high-growth areas. Notable transactions in 2023 included the sale of operations in Argentina and various outpatient cardiovascular clinics in the U.S., which are projected to streamline the company's focus and improve its financial leverage.

Further bolstering its market presence, Fresenius Medical Care received FDA clearance for its 5008X Hemodialysis System, aiming to set a new standard in U.S. dialysis therapy. This innovative system, combined with high-volume hemodiafiltration techniques, has shown to significantly reduce mortality rates among dialysis patients, according to the multinational CONVINCE study.

Financially, Fresenius Medical Care remains robust, with initiatives like the FME25 transformation program driving sustainable cost savings and operational efficiency. The company’s commitment to disciplined capital allocation and strategic growth is evident in its latest annual results, which showed improved margins and a strong cash flow position.

Looking forward, Fresenius Medical Care is set to achieve further growth and operational excellence. With continued investment in technological advancements, strategic divestitures, and a focus on high-value markets, the company aims to enhance profitability and support its long-term sustainability goals.

News

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Rhea-AI Summary
Fresenius Medical Care (FME) delivers on commitments during a year of fundamental transformation, making progress towards sustainability goals in key areas such as patient satisfaction, diversity in management, and climate target roadmap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Rhea-AI Summary
Fresenius Medical Care introduces Augmented Reality (AR) training application for ICU staff to enhance learning experience and address nursing shortages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
News

Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

Rhea-AI Summary
Fresenius Medical Care appoints Jörg Häring as Global Head of Legal, Compliance, and Human Resources, effective June 1, 2024. Häring brings extensive expertise in corporate governance and legal matters from his previous roles in the energy and healthcare sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
management
News

Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Rhea-AI Summary
Fresenius Medical Care sells dialysis clinic networks in Latin America to DaVita Inc. for USD 300 million, impacting revenue and profitability negatively in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.19%
Tags
none
-
News

Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Rhea-AI Summary
Fresenius Medical Care reports revenue growth of 5% in 2023 driven by favorable business development and operating income growth of 15%, exceeding expectations. The company successfully executed a turnaround plan resulting in labor productivity improvements and positive pricing. Key divestments were announced, leading to strong cash flow performance and reduced financial leverage. A dividend of €1.19 per share is proposed, with continued revenue and accelerated operating income growth projected for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
-
News

Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Rhea-AI Summary
Fresenius Medical Care (FME) has received FDA 510(k) clearance for its 5008X Hemodialysis System, allowing the company to offer high-volume hemodiafiltration therapy in the U.S. The system is expected to be launched in 2025, aiming to bring a new standard of care in dialysis therapy to the U.S. market. The groundbreaking CONVINCE study showed a 23% decrease in mortality rates for patients treated with high-volume hemodiafiltration compared to high-flux hemodialysis. The company's global innovation leadership in medical device and membrane engineering technologies is highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
News

Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Rhea-AI Summary
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives to its Supervisory Board. This move comes after the company's change of legal form into a German stock corporation and aims to provide full and equal representation on the board. The Board now comprises six women and six men, exceeding the statutory minimum gender quota for the Supervisory Board of 30 percent each. The appointed members bring a broad range of experience and knowledge to the Board, aiming to further develop Fresenius Medical Care successfully for the benefit of patients, employees, and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
News

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Rhea-AI Summary
Fresenius Medical Care (FME) announces divestments as part of its Portfolio Optimization Program, with a focus on improving leverage ratio and simplifying the company's portfolio. The company has already closed transactions in Argentina and the US, with additional divestments in progress. The divested assets include 127 facilities, more than 4,500 employees, and more than 10,000 dialysis patients, representing a total proforma revenue of around EUR 600 million in 2022. The company expects net proceeds of around EUR 500 million from the divestments, with the remainder to occur in 2024. However, the divestments are estimated to negatively impact 2025 revenue by EUR 1.5 billion but positively impact 2025 margin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
News

Fresenius Medical Care completes change of legal form into a German stock corporation

Rhea-AI Summary
Fresenius Medical Care (FMS) completes change of legal form to Aktiengesellschaft (AG), strengthening corporate governance structure, free float shareholders, and flexibility. The Management Board remains unchanged, while the new Supervisory Board takes office immediately. The business model and strategic plan continue to drive improved operating performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
News

Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

Rhea-AI Summary
Fresenius Medical Care (FME, FMS) resolves legal dispute with the U.S. government, expecting a net positive impact on operating income of approx. EUR 175 million in Q4 2023. The company raises its earnings outlook, anticipating a 12 to 14 percent growth in operating income in fiscal year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
earnings

FAQ

What is the current stock price of Fresenius Medical Care (FMS)?

The current stock price of Fresenius Medical Care (FMS) is $21.79 as of November 20, 2024.

What is the market cap of Fresenius Medical Care (FMS)?

The market cap of Fresenius Medical Care (FMS) is approximately 12.6B.

What does Fresenius Medical Care AG & Co. KGaA specialize in?

Fresenius Medical Care specializes in providing kidney dialysis services and products, operating over 4,100 clinics worldwide and holding a 35% share of the global dialysis products market.

How many patients does Fresenius Medical Care treat annually?

The company treats approximately 345,000 patients annually across its global network of dialysis clinics.

What percentage of Fresenius Medical Care's revenue comes from services?

Around 80% of the company's revenue comes from services, which include care coordination and ancillary operations.

What is the Portfolio Optimization Program?

The Portfolio Optimization Program is Fresenius Medical Care's strategic initiative to focus on high-growth, sustainable markets and divest non-core and less profitable assets.

What are some recent achievements of Fresenius Medical Care?

Recent achievements include the FDA clearance of its 5008X Hemodialysis System in the U.S. and significant divestitures aimed at improving financial leverage and focusing on core markets.

What is the 5008X Hemodialysis System?

The 5008X Hemodialysis System is an advanced dialysis machine designed to improve patient outcomes with high-volume hemodiafiltration techniques, recently cleared by the FDA for use in the U.S.

How does the FME25 transformation program benefit Fresenius Medical Care?

The FME25 transformation program aims to drive sustainable cost savings and improve operational efficiency, contributing to better financial performance and margins.

What are Fresenius Medical Care's sustainability goals?

The company aims to achieve climate neutrality in its operations by 2040, aligning with the Paris Agreement, and maintains a high Net Promoter Score for patient satisfaction.

Where is Fresenius Medical Care listed?

Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).

What are the expected financial growth rates for Fresenius Medical Care in 2024?

The company expects revenue to grow by a low- to mid-single digit percent rate and operating income to grow by a mid- to high-teens percent rate in 2024.

Stock FMS logo
Fresenius Medical Care AG

NYSE:FMS

FMS Rankings

#741 Ranked by Market Cap
#1062 Ranked by Dividends

FMS Stock Data

12.62B
586.83M
7.4%
0.17%
Medical Care Facilities
Healthcare
Link
United States of America
Bad Homburg